Are Supplemental Branched-Chain Amino Acids Beneficial During the Oncological Peri-Operative Period: A Systematic Review and Meta-Analysis.

Cogo, E; Elsayed, M; Liang, V; Cooley, K; Guerin, C; Psihogios, A; Papadogianis, P

Are Supplemental Branched-Chain Amino Acids Beneficial During the Oncological Peri-Operative Period: A Systematic Review and Meta-Analysis.

Cogo, E Elsayed, M Liang, V Cooley, K

Guerin, C Psihogios, A Papadogianis, P

Permalink

Publisher:: SAGE PUBLICATIONS INC
Publication Type:: Journal Article
Citation:: Integrative Cancer Therapies, 2021, 20, pp. 1534735421997551
Issue Date:: 2021-01-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.89 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Cogo, E
dc.contributor.author	Elsayed, M
dc.contributor.author	Liang, V
dc.contributor.author	Cooley, K https://orcid.org/0000-0001-7960-6504
dc.contributor.author	Guerin, C
dc.contributor.author	Psihogios, A
dc.contributor.author	Papadogianis, P
dc.date.accessioned	2021-09-09T04:15:06Z
dc.date.available	2021-09-09T04:15:06Z
dc.date.issued	2021-01-01
dc.identifier.citation	Integrative Cancer Therapies, 2021, 20, pp. 1534735421997551
dc.identifier.issn	1534-7354
dc.identifier.issn	1552-695X
dc.identifier.uri	http://hdl.handle.net/10453/150422
dc.description.abstract	<h4>Background</h4>Branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) are essential amino acids involved in immune responses, and may have roles in protein malnutrition and sarcopenia. Furthermore, certain liver diseases have been associated with a decreased Fischer's ratio (BCAAs to aromatic amino acids; phenylalanine, tyrosine, and tryptophan). We aimed to evaluate the safety and efficacy of BCAAs use in patients with cancer undergoing surgery.<h4>Methods</h4>MEDLINE, Embase, and CENTRAL were searched (inception to July 24, 2020) for randomized controlled trials (RCTs) and comparative observational studies in English evaluating BCAAs (alone or in combinations) during the oncological peri-operative period. Study selection, data extraction, and quality appraisal were done in duplicate. RCT risk-of-bias was appraised using Cochrane Risk-of-Bias tool, and observational studies' quality assessment was conducted with Newcastle-Ottawa Scale. Meta-analyses were conducted when appropriate.<h4>Results</h4>20 articles were included comprising 13 RCTs and 6 observational cohort studies in 7 reports and 2019 total participants overall. Among 13 RCTs, 77% involved liver cancer. Methodological study quality scored substantial risk-of-bias across most RCTs. Meta-analysis of RCTs found a 38% decreased risk of post-operative infections in BCAAs group compared to controls (RR = 0.62; 95% CI = 0.44 to 0.87; <i>P</i> = .006; number of RCTs, <i>k</i> = 6; total sample size, N = 389; <i>I</i><sup>2</sup> = 0%). BCAAs were also found to be beneficial for ascites (RR = 0.55; 95% CI = 0.35 to 0.86; <i>P</i> = .008; <i>k</i> = 4; N = 296; <i>I</i><sup>2</sup> = 0%), body weight (MD = 3.24 kg; 95% CI = 0.44 to 6.04; <i>P</i> = .02; <i>k</i> = 3; N = 196; <i>I</i><sup>2</sup> = 24%), and hospitalization length (MD = -2.07 days; 95% CI = -3.97 to -0.17; <i>P</i> = .03; <i>k</i> = 5; N = 362; <i>I</i><sup>2</sup> = 59%). No differences were found between BCAAs and controls for mortality, recurrence, other post-operative complications (liver failure, edema, pleural effusion), blood loss, quality of life, ammonia level, and prothrombin time. No serious adverse events were related to BCAAs; however, serious adverse events were reported due to intravenous catheters. No safety concerns from observational studies were identified.<h4>Conclusions</h4>Branched-chain amino acids during the oncological surgical period demonstrated promise in reducing important post-operative morbidity from infections and ascites compared to controls. Blinded, placebo-controlled confirmatory trials of higher methodological quality are warranted, especially using oral, short-term BCAAs-enriched supplements within the context of recent ERAS programs.<h4>Prospero registration</h4>CRD42018086168.
dc.format	Print
dc.language	eng
dc.publisher	SAGE PUBLICATIONS INC
dc.relation.ispartof	Integrative Cancer Therapies
dc.relation.isbasedon	10.1177/1534735421997551
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1104 Complementary and Alternative Medicine, 1112 Oncology and Carcinogenesis
dc.subject.classification	Complementary & Alternative Medicine
dc.title	Are Supplemental Branched-Chain Amino Acids Beneficial During the Oncological Peri-Operative Period: A Systematic Review and Meta-Analysis.
dc.type	Journal Article
utslib.citation.volume	20
utslib.location.activity	United States
utslib.for	1104 Complementary and Alternative Medicine
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	open_access	*
dc.date.updated	2021-09-09T04:15:01Z
pubs.publication-status	Published
pubs.volume	20

Abstract:

Background

Branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) are essential amino acids involved in immune responses, and may have roles in protein malnutrition and sarcopenia. Furthermore, certain liver diseases have been associated with a decreased Fischer's ratio (BCAAs to aromatic amino acids; phenylalanine, tyrosine, and tryptophan). We aimed to evaluate the safety and efficacy of BCAAs use in patients with cancer undergoing surgery.

Methods

MEDLINE, Embase, and CENTRAL were searched (inception to July 24, 2020) for randomized controlled trials (RCTs) and comparative observational studies in English evaluating BCAAs (alone or in combinations) during the oncological peri-operative period. Study selection, data extraction, and quality appraisal were done in duplicate. RCT risk-of-bias was appraised using Cochrane Risk-of-Bias tool, and observational studies' quality assessment was conducted with Newcastle-Ottawa Scale. Meta-analyses were conducted when appropriate.

Results

20 articles were included comprising 13 RCTs and 6 observational cohort studies in 7 reports and 2019 total participants overall. Among 13 RCTs, 77% involved liver cancer. Methodological study quality scored substantial risk-of-bias across most RCTs. Meta-analysis of RCTs found a 38% decreased risk of post-operative infections in BCAAs group compared to controls (RR = 0.62; 95% CI = 0.44 to 0.87; P = .006; number of RCTs, k = 6; total sample size, N = 389; I² = 0%). BCAAs were also found to be beneficial for ascites (RR = 0.55; 95% CI = 0.35 to 0.86; P = .008; k = 4; N = 296; I² = 0%), body weight (MD = 3.24 kg; 95% CI = 0.44 to 6.04; P = .02; k = 3; N = 196; I² = 24%), and hospitalization length (MD = -2.07 days; 95% CI = -3.97 to -0.17; P = .03; k = 5; N = 362; I² = 59%). No differences were found between BCAAs and controls for mortality, recurrence, other post-operative complications (liver failure, edema, pleural effusion), blood loss, quality of life, ammonia level, and prothrombin time. No serious adverse events were related to BCAAs; however, serious adverse events were reported due to intravenous catheters. No safety concerns from observational studies were identified.

Conclusions

Branched-chain amino acids during the oncological surgical period demonstrated promise in reducing important post-operative morbidity from infections and ascites compared to controls. Blinded, placebo-controlled confirmatory trials of higher methodological quality are warranted, especially using oral, short-term BCAAs-enriched supplements within the context of recent ERAS programs.

Prospero registration

CRD42018086168.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150422